{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:08:02Z","timestamp":1790032082437,"version":"4.0.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A major goal of immunotherapy remains the control of pathogenic T cell responses that drive autoimmunity and allograft rejection. Adherent progenitor cells, including mesenchymal stromal cells (MSCs) and multipotent adult progenitor cells (MAPCs), represent attractive immunomodulatory cell therapy candidates currently active in clinical trials. MAPCs can be distinguished from MSCs on the basis of cellular phenotype, size, transcriptional profile, and expansion capacity. However, despite their ongoing evaluation in autoimmune and allogeneic solid organ transplantation settings, data supporting the immune regulatory potential of clinical-grade MAPCs are limited. In this study, we used allogeneic islet transplantation as a model indication to assess the ability of clinical-grade MAPCs to control T cell responses that drive immunopathology in human autoimmune disease and allograft rejection. MAPCs suppressed T cell proliferation and Th1 and Th17 cytokine production while increasing secretion of IL-10 and were able to suppress effector functions of bona fide autoreactive T cells from individuals with type 1 diabetes mellitus, including killing of human islets. Furthermore, MAPCs favored the proliferation of regulatory T cells during homeostatic expansion driven by \u03b3-chain cytokines and exerted a durable, yet reversible, control of T cell function. MAPC suppression required licensing and proceeded via IDO-mediated tryptophan catabolism. Therefore, the common immune modulatory characteristics of clinical-grade MAPCs shown in this study suggest that they can be regarded as an alternative source of adult progenitor cells with similar clinical usefulness to MSCs. Taken collectively, these findings may guide the successful deployment of both MSCs and MAPCs for the amelioration of human autoimmunity and allograft rejection.<\/jats:p>","DOI":"10.4049\/jimmunol.1202710","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T01:21:20Z","timestamp":1364865680000},"page":"4542-4552","source":"Crossref","is-referenced-by-count":68,"title":["Clinical-Grade Multipotent Adult Progenitor Cells Durably Control Pathogenic T Cell Responses in Human Models of Transplantation and Autoimmunity"],"prefix":"10.1093","volume":"190","author":[{"given":"James L","family":"Reading","sequence":"first","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie H M","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Sabbah","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Skowera","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin R","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jef","family":"Pinxteren","sequence":"additional","affiliation":[{"name":"ReGenesys, Bioincubator Leuven , 3001 Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Vaes","sequence":"additional","affiliation":[{"name":"ReGenesys, Bioincubator Leuven , 3001 Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Allsopp","sequence":"additional","affiliation":[{"name":"Neusentis Regenerative Medicine, Pfizer Ltd. , Great Abington, Cambridge CB21 6GP,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E","family":"Ting","sequence":"additional","affiliation":[{"name":"Athersys, Inc. , Cleveland, OH 44115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Busch","sequence":"additional","affiliation":[{"name":"Athersys, Inc. , Cleveland, OH 44115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Raber","sequence":"additional","affiliation":[{"name":"Athersys, Inc. , Cleveland, OH 44115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Deans","sequence":"additional","affiliation":[{"name":"Athersys, Inc. , Cleveland, OH 44115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy I M","family":"Tree","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, King\u2019s College London, Guy\u2019s Hospital , London SE1 9RT,","place":["United Kingdom"]},{"name":"National Institutes of Health Research Biomedical Research Centre at Guy\u2019s and St. Thomas\u2019 National Health Service Foundation Trust and King\u2019s College London , London SE1 9RT,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,1]]},"reference":[{"key":"2025032406582984100_r1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/jcb.23119","article-title":"Allogeneic mesenchymal stem cells: agents of immune modulation","volume":"112","author":"English","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"2025032406582984100_r2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/stem.269","article-title":"Mesenchymal stromal cells: current understanding and clinical status","volume":"28","author":"Salem","year":"2010","journal-title":"Stem Cells"},{"key":"2025032406582984100_r3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri3209","article-title":"Multipotent mesenchymal stromal cells and the innate immune system","volume":"12","author":"Le Blanc","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"2025032406582984100_r4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2025032406582984100_r5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2011.01.006","article-title":"Multipotent adult progenitor cells","volume":"24","author":"Sohni","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2025032406582984100_r6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/icb.2012.64","article-title":"Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells","volume":"91","author":"Jacobs","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"2025032406582984100_r7","first-page":"17","article-title":"Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell","volume":"4","author":"Boozer","year":"2009","journal-title":"J. Stem Cells"},{"key":"2025032406582984100_r8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/14653240802320245","article-title":"Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells","volume":"10","author":"Kovacsovics-Bankowski","year":"2008","journal-title":"Cytotherapy"},{"key":"2025032406582984100_r9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.bbrc.2004.11.059","article-title":"Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation","volume":"326","author":"Abdallah","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025032406582984100_r10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fimmu.2012.00345","article-title":"Application of MultiStem(\u00ae) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease","volume":"3","author":"Vaes","year":"2012","journal-title":"Front. Immunol."},{"key":"2025032406582984100_r11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3727\/096368911X603657","article-title":"Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction","volume":"21","author":"Medicetty","year":"2012","journal-title":"Cell Transplant."},{"key":"2025032406582984100_r12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOT.0b013e32835c2adf","article-title":"Mesenchymal stromal cells as a means of controlling pathological T-cell responses in allogeneic islet transplantation","volume":"18","author":"Reading","year":"2013","journal-title":"Curr. Opin. Organ Transplant."},{"key":"2025032406582984100_r13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/B:JOCI.0000018065.64685.82","article-title":"Cellular immune activation in Gulf War veterans","volume":"24","author":"Skowera","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"2025032406582984100_r14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI19585","article-title":"Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health","volume":"113","author":"Arif","year":"2004","journal-title":"J. Clin. Invest."},{"key":"2025032406582984100_r15","first-page":"3390","article-title":"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. [Published erratum appears in 2009 J. Clin. Invest. 119: 2844.]","volume":"118","author":"Skowera","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025032406582984100_r16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0022-1759(96)00063-4","article-title":"Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand","volume":"193","author":"Blomberg","year":"1996","journal-title":"J. Immunol. Methods"},{"key":"2025032406582984100_r17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2337\/db12-0315","article-title":"Human \u03b2-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity","volume":"62","author":"Knight","year":"2013","journal-title":"Diabetes"},{"key":"2025032406582984100_r18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2337\/diabetes.48.3.484","article-title":"Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients","volume":"48","author":"Roep","year":"1999","journal-title":"Diabetes"},{"key":"2025032406582984100_r19","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2337\/db10-1643","article-title":"Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated \u03b2-cell death","volume":"60","author":"Arif","year":"2011","journal-title":"Diabetes"},{"key":"2025032406582984100_r20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2337\/db09-0503","article-title":"Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression","volume":"59","author":"Tree","year":"2010","journal-title":"Diabetes"},{"key":"2025032406582984100_r21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.tp.0000229448.64363.18","article-title":"The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients","volume":"82","author":"van den Boogaardt","year":"2006","journal-title":"Transplantation"},{"key":"2025032406582984100_r22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1034\/j.1600-065X.2001.1820113.x","article-title":"The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance","volume":"182","author":"Zelenika","year":"2001","journal-title":"Immunol. Rev."},{"key":"2025032406582984100_r23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1600-6143.2008.02479.x","article-title":"Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation","volume":"9","author":"Huurman","year":"2009","journal-title":"Am. J. Transplant."},{"key":"2025032406582984100_r24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2249.2008.03810.x","article-title":"Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes","volume":"154","author":"Lawson","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"2025032406582984100_r25","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.4049\/jimmunol.181.10.7350","article-title":"The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells","volume":"181","author":"Schneider","year":"2008","journal-title":"J. Immunol."},{"key":"2025032406582984100_r26","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.180.6.3910","article-title":"Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection","volume":"180","author":"Moxham","year":"2008","journal-title":"J. Immunol."},{"key":"2025032406582984100_r27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beha.2006.09.008","article-title":"Autoimmunity following haematopoietic stem-cell transplantation","volume":"20","author":"Daikeler","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2025032406582984100_r28","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J. Clin. Invest."},{"key":"2025032406582984100_r29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1600-6143.2007.02134.x","article-title":"CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H","volume":"8","author":"Bloom","year":"2008","journal-title":"Am. J. Transplant."},{"key":"2025032406582984100_r30","first-page":"1806","article-title":"Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells","volume":"118","author":"Monti","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025032406582984100_r31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cellimm.2012.01.008","article-title":"FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy","volume":"274","author":"Hire","year":"2012","journal-title":"Cell. Immunol."},{"key":"2025032406582984100_r32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3727\/096368910X508762","article-title":"Mesenchymal stem cells: Mechanisms of immunomodulation and homing","volume":"19","author":"Yagi","year":"2010","journal-title":"Cell Transplant."},{"key":"2025032406582984100_r33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-bioeng-070909-105309","article-title":"Mesenchymal stem cells as therapeutics","volume":"12","author":"Parekkadan","year":"2010","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"2025032406582984100_r34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/stem.633","article-title":"Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions","volume":"29","author":"Roobrouck","year":"2011","journal-title":"Stem Cells"},{"key":"2025032406582984100_r35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/stem.603","article-title":"Concise review: culture mediated changes in fate and\/or potency of stem cells","volume":"29","author":"Roobrouck","year":"2011","journal-title":"Stem Cells"},{"key":"2025032406582984100_r36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2009-03-213850","article-title":"Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming","volume":"114","author":"Highfill","year":"2009","journal-title":"Blood"},{"key":"2025032406582984100_r37","doi-asserted-by":"crossref","first-page":"e43683","DOI":"10.1371\/journal.pone.0043683","article-title":"Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice","volume":"7","author":"Mora-Lee","year":"2012","journal-title":"PLoS ONE"},{"key":"2025032406582984100_r38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cellimm.2008.10.004","article-title":"Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease","volume":"255","author":"Kovacsovics-Bankowski","year":"2009","journal-title":"Cell. Immunol."},{"key":"2025032406582984100_r39","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"Meisel","year":"2004","journal-title":"Blood"},{"key":"2025032406582984100_r40","doi-asserted-by":"publisher","DOI":"10.3727\/096368912X657369","article-title":"Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses","volume-title":"Cell Transplant.","author":"Jacobs","year":"2012"},{"key":"2025032406582984100_r41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/icb.2012.56","article-title":"Mechanisms of mesenchymal stromal cell immunomodulation","volume":"91","author":"English","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"2025032406582984100_r42","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/eji.200839070","article-title":"Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells","volume":"39","author":"Guo","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"2025032406582984100_r43","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/eji.201141499","article-title":"Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor","volume":"41","author":"Duffy","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"2025032406582984100_r44","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4049\/jimmunol.0902007","article-title":"Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype","volume":"185","author":"Ghannam","year":"2010","journal-title":"J. Immunol."},{"key":"2025032406582984100_r45","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/stem.406","article-title":"Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells","volume":"28","author":"Tso","year":"2010","journal-title":"Stem Cells"},{"key":"2025032406582984100_r46","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3109\/14653249.2010.542456","article-title":"Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation","volume":"13","author":"Tatara","year":"2011","journal-title":"Cytotherapy"},{"key":"2025032406582984100_r47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.imlet.2010.09.006","article-title":"Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation","volume":"135","author":"Carri\u00f3n","year":"2011","journal-title":"Immunol. Lett."},{"key":"2025032406582984100_r48","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22065","article-title":"Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis","volume":"68","author":"Darlington","year":"2010","journal-title":"Ann. Neurol."},{"key":"2025032406582984100_r49","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1210\/jc.2009-2350","article-title":"Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes","volume":"95","author":"Zanone","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025032406582984100_r50","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2008.094003","article-title":"Human bone marrow mesenchymal stem cells and chondrocytes promote and\/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15","volume":"68","author":"Bocelli-Tyndall","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2025032406582984100_r51","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","article-title":"Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli","volume":"99","author":"Di Nicola","year":"2002","journal-title":"Blood"},{"key":"2025032406582984100_r52","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2002-07-2104","article-title":"Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide","volume":"101","author":"Krampera","year":"2003","journal-title":"Blood"},{"key":"2025032406582984100_r53","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2004-09-3696","article-title":"Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells","volume":"105","author":"Glennie","year":"2005","journal-title":"Blood"},{"key":"2025032406582984100_r54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"2025032406582984100_r55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3727\/215517911X593100","article-title":"Mesenchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus","volume":"2","author":"Busch","year":"2011","journal-title":"Cell Medicine"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/190\/9\/4542\/62501135\/1202710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/190\/9\/4542\/62501135\/1202710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T07:32:05Z","timestamp":1742974325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/190\/9\/4542\/8004196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1202710","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,5]]},"published":{"date-parts":[[2013,5,1]]}}}